In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with ...

P1101 had durable hematologic responses and manageable safety among patients with essential thrombocythemia, meeting the primary end goal of SURPASS-ET. Among patients with essential thrombocythemia ...

Two hundred and seventy-five subjects were identified. Among these, 133 (63 male and 70 female, mean age 68.4 ± 9.3) subjects were excluded (19 due to neoplasm, 34 due to multiple trauma, 14 due ...

The SURPASS-ET trial (NCT04285086) of ropeginterferon alfa-2b-njft (P1101; Besremi) in patients with essential thrombocythemia (ET) has met its primary end point, yielding durable clinical response as ...

Those with infections, malignancy, neurological diseases, renal and liver failure, osteomyelitis, multiple trauma, rheumathoid arthritis, primary thrombocytosis or previously ascertained blood ...

Myeloproliferative neoplasms are blood cancers that affect myeloid stem cells. Treatment can involve targeted medications or careful monitoring. Myeloproliferative disorders are a group of cancers ...